8.27

0.72% -0.06

Adaptive Biotechnologies Corp (ADPT)

Overview News Price History Option Chain Financials Why ADPT Down? Discussions Forecast

Adaptive Biotechnologies Corp stock is traded at $8.27, with a volume of 1.38M. It is down -0.72% in the last 24 hours and up +11.01% over the past month. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Previous Close:

$8.33

Open:

$8.47

24h Volume:

1.38M

Relative Volume:

0.98

Market Cap:

$1.22B

Revenue:

$177.28M

Net Income/Loss:

$-195.24M

P/E Ratio:

-6.1716

EPS:

-1.34

Net Cash Flow:

$-114.54M

1W Performance:

-0.72%

1M Performance:

+11.01%

6M Performance:

+79.39%

1Y Performance:

+116.49%

1-Day Range:

$8.09

$8.62

1-Week Range:

$8.09

$8.95

52-Week Range:

$2.28

$8.95

Adaptive Biotechnologies Corp Stock (ADPT) Company Profile

Name

Adaptive Biotechnologies Corp

Sector

Healthcare (1169)

Industry

Biotechnology (678)

Phone

206-659-0067

Address

1165 EASTLAKE AVE E, SEATTLE, WA

Employee

709

Twitter

@adaptivebiotech

Next Earnings Date

2025-02-11

Latest SEC Filings

ADPT's Discussions on Twitter

Compare ADPT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADPT Adaptive Biotechnologies Corp	8.27	1.22B	177.28M	-195.24M	-114.54M	-1.34
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-05-23	Resumed	JP Morgan	Overweight
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Dec-21-22	Upgrade	Piper Sandler	Neutral → Overweight
Aug-25-22	Initiated	Credit Suisse	Underperform
Jun-03-22	Initiated	Piper Sandler	Neutral
Feb-16-22	Reiterated	BTIG Research	Buy
Feb-16-22	Reiterated	BofA Securities	Buy
Feb-16-22	Reiterated	Goldman	Neutral
Feb-16-22	Reiterated	JP Morgan	Overweight
Oct-15-21	Resumed	Cowen	Outperform
Mar-03-21	Downgrade	Goldman	Buy → Neutral
Oct-08-20	Resumed	BTIG Research	Buy
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight
Jun-03-20	Initiated	Goldman	Buy
Jul-23-19	Initiated	BTIG Research	Buy
Jul-22-19	Initiated	BofA/Merrill	Buy
Jul-22-19	Initiated	Cowen	Outperform
Jul-22-19	Initiated	Goldman	Neutral
Jul-22-19	Initiated	Guggenheim	Buy
Jul-22-19	Initiated	William Blair	Outperform

View All

Adaptive Biotechnologies Corp Stock (ADPT) Latest News

12:57 PM

Cathie Wood’s Ark Invest Makes Bold Moves: Buys BEAM & NU, Sells MELI & ADPT - Apna Kal

12:57 PM

04:05 AM

Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies - Benzinga India

04:05 AM

Feb 21, 2025

Adaptive Biotechnologies CEO Chad Robins sells over $2.4m in stock - Investing.com Nigeria

Feb 21, 2025

Feb 20, 2025

Cathie Wood's ARK buys Beam Therapeutics, sells Adaptive Biotech stock By Investing.com - Investing.com Australia

Feb 20, 2025

Cathie Wood's ARK buys Beam Therapeutics, sells Adaptive Biotech stock - Investing.com India

Feb 20, 2025

Feb 18, 2025

Adaptive Biotechnologies CEO Chad Robins sells $3.99 million in shares By Investing.com - Investing.com Nigeria

Feb 18, 2025

Adaptive Biotechnologies CEO Chad Robins sells $3.99 million in shares - Investing.com

Feb 18, 2025

Adaptive Biotechnologies CEO Chad M Robins Sells Over $3.9 Million in Company Stock - TradingView

Feb 18, 2025

Feb 17, 2025

ADPT stock soars to 52-week high, reaching $8.33 - MSN

Feb 17, 2025

Feb 15, 2025

Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Up 7.9% Following Analyst Upgrade - Armenian Reporter

Feb 15, 2025

Scotiabank Forecasts Strong Price Appreciation for Adaptive Biotechnologies (NASDAQ:ADPT) Stock - Defense World

Feb 15, 2025

Feb 14, 2025

Legato Capital Management LLC Decreases Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat

Feb 14, 2025

Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Up 7.9% on Analyst Upgrade - MarketBeat

Feb 14, 2025

Scotiabank Issues Positive Forecast for Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price - MarketBeat

Feb 14, 2025

Adaptive Biotechnologies price target raised to $12 from $10 at Scotiabank - Yahoo Finance

Feb 14, 2025

Adaptive Biotechnologies targets $1,300 ASP for MRD tests in 2025 driven by pricing improvements - MSN

Feb 14, 2025

Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates - MSN

Feb 14, 2025

Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat

Feb 14, 2025

Adaptive Biotechnologies (NASDAQ:ADPT) Reaches New 1-Year High After Analyst Upgrade - MarketBeat

Feb 14, 2025

Feb 13, 2025

Adaptive Biotechnologies (NASDAQ:ADPT) Shares Down 5.2%Time to Sell? - MarketBeat

Feb 13, 2025

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 13, 2025

Feb 12, 2025